Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nathan Turnbull

Orthopaedic Surgery Deland, FL Medical Doctor

NPI 1144451055 CMS profile 142612

740 W Plymouth Ave, Deland, FL 32720

Open in the dashboard

General payments

$3,798

130 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nathan Turnbull of Deland, FL is reported in the CMS Open Payments database as having received $3,798 across 130 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 51st percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $195 7
2024 General $535 17
2023 General $668 14
2022 General $798 26
2021 General $606 26
2020 General $417 13
2019 General $578 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nathan Turnbull
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Nathan Turnbull were reported at $195. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Nathan Turnbull Orthopaedic Surgery median Middle half National median
2019 $578 $644 $140–$2,844 $163
2020 $417 $312 $75–$1,860 $114
2021 $606 $520 $117–$2,495 $132
2022 $798 $598 $128–$2,731 $149
2023 $668 $461 $128–$2,264 $160
2024 $535 $497 $134–$2,475 $164
2025 $195 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $2,515 74 payments
  2. DePuy Synthes Sales Inc. $247 6 payments
  3. Smith+Nephew, Inc. $169 9 payments
  4. Arthrex, Inc. $119 1 payment
  5. Amgen Inc. $81 5 payments
  6. Ferring Pharmaceuticals Inc. $75 5 payments
  7. Heraeus Medical, LLC. $62 4 payments
  8. Flexion Therapeutics, Inc. $60 3 payments
  9. ERMI Inc. $56 2 payments
  10. Pacira Pharmaceuticals Incorporated $56 3 payments
  11. Other $358 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,781 129 payments
  2. Education $16 1 payment
Products named General payments · program years 2019–2025
  1. NA $734 26 payments
  2. MAKO Knees, Hips $308 4 payments
  3. HOFFMANN $301 6 payments
  4. INSIGNIA $246 6 payments
  5. BIOLOGICS CONSUMABLES ACCESSORIES ANGEL PRP $119 1 payment
  6. MAKO Knees, Hips $99 3 payments
  7. EVENITY $81 5 payments
  8. EUFLEXXA $75 5 payments
  9. AEQUALIS $71 1 payment
  10. AXSOS $68 1 payment
  11. Other $1,541 73 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

1,367

Median for Orthopedic Surgery: 203

Drug cost

$18,792

Median for Orthopedic Surgery: $1,433

Branded share of claims

24.4%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 15 $4,995
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 261 $4,133
Diclofenac Sodium Generic 161 $1,760
Tramadol Hcl Generic 268 $1,550
Enoxaparin Sodium Generic 16 $1,202
Celecoxib Generic 81 $1,057
Ondansetron Hcl Generic 49 $633
Doxycycline Monohydrate Generic 41 $601
Cephalexin Generic 92 $583
Amoxicillin Generic 174 $435

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$348,512

Of which drugs: $14,245

Medicare patients

745

Average age 76

Services billed

6,116

467 women, 278 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 31%
Diabetes 29%
Chronic kidney disease 28%
Depression 22%
Atrial fibrillation 20%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose J7321 Office 48 221 $12,179
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 320 2,311 $1,722

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EVENITY
  • Amgen Inc. $16
$16 — —
ELIQUIS
  • PFIZER INC. $7
$7 15 —
NURTEC ODT
  • PFIZER INC. $7
$7 — —
PAXLOVID
  • PFIZER INC. $7
$7 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

130 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record